Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Out-of-Hospital Cardiac Arrest | 12 | 2023 | 346 | 2.920 |
Why?
|
| Cardiopulmonary Resuscitation | 10 | 2023 | 1001 | 1.880 |
Why?
|
| Heart Arrest | 7 | 2022 | 1503 | 0.920 |
Why?
|
| Angioplasty, Balloon, Coronary | 6 | 2023 | 1880 | 0.780 |
Why?
|
| Coronary Angiography | 17 | 2023 | 4560 | 0.680 |
Why?
|
| Coma | 4 | 2016 | 487 | 0.620 |
Why?
|
| Drug-Eluting Stents | 3 | 2023 | 758 | 0.610 |
Why?
|
| Coronary Restenosis | 1 | 2018 | 425 | 0.490 |
Why?
|
| Coronary Artery Disease | 13 | 2023 | 6649 | 0.490 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2018 | 556 | 0.470 |
Why?
|
| Platelet Aggregation Inhibitors | 11 | 2017 | 3193 | 0.440 |
Why?
|
| Platelet Aggregation | 6 | 2016 | 800 | 0.430 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2020 | 1453 | 0.400 |
Why?
|
| Paris | 8 | 2020 | 50 | 0.400 |
Why?
|
| Myocardial Infarction | 10 | 2020 | 11888 | 0.380 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2022 | 1572 | 0.360 |
Why?
|
| Fractional Flow Reserve, Myocardial | 3 | 2020 | 331 | 0.320 |
Why?
|
| Acute Coronary Syndrome | 6 | 2023 | 2363 | 0.320 |
Why?
|
| Aspirin | 7 | 2016 | 3360 | 0.300 |
Why?
|
| Ticlopidine | 6 | 2016 | 895 | 0.290 |
Why?
|
| Thrombosis | 1 | 2019 | 3043 | 0.240 |
Why?
|
| Emergency Medical Services | 4 | 2023 | 1927 | 0.230 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 3 | 2016 | 380 | 0.220 |
Why?
|
| Electrocardiography | 4 | 2013 | 6400 | 0.220 |
Why?
|
| Sports | 2 | 2019 | 700 | 0.210 |
Why?
|
| Adenosine | 3 | 2016 | 832 | 0.200 |
Why?
|
| Coronary Stenosis | 3 | 2020 | 818 | 0.190 |
Why?
|
| France | 4 | 2018 | 510 | 0.180 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 2420 | 0.180 |
Why?
|
| Cardiology | 2 | 2021 | 1720 | 0.180 |
Why?
|
| Registries | 7 | 2022 | 8434 | 0.180 |
Why?
|
| Stents | 4 | 2023 | 3308 | 0.170 |
Why?
|
| Hypothermia, Induced | 2 | 2016 | 758 | 0.170 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 6853 | 0.170 |
Why?
|
| Treatment Outcome | 19 | 2023 | 64879 | 0.170 |
Why?
|
| Swine | 4 | 2019 | 5903 | 0.170 |
Why?
|
| Thiophenes | 3 | 2015 | 587 | 0.170 |
Why?
|
| Peritoneal Dialysis | 1 | 2020 | 157 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2020 | 2253 | 0.160 |
Why?
|
| Blood Platelets | 3 | 2016 | 2522 | 0.160 |
Why?
|
| Peritonitis | 1 | 2020 | 370 | 0.150 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 6311 | 0.150 |
Why?
|
| Platelet Function Tests | 6 | 2016 | 294 | 0.140 |
Why?
|
| Assisted Circulation | 1 | 2017 | 102 | 0.140 |
Why?
|
| Microcirculation | 2 | 2019 | 1277 | 0.140 |
Why?
|
| Sirolimus | 1 | 2023 | 1548 | 0.140 |
Why?
|
| Angioplasty | 1 | 2019 | 360 | 0.130 |
Why?
|
| Retrospective Studies | 11 | 2020 | 80121 | 0.130 |
Why?
|
| Infarction | 1 | 2017 | 248 | 0.130 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2018 | 320 | 0.130 |
Why?
|
| Middle Aged | 28 | 2020 | 219653 | 0.130 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2018 | 316 | 0.120 |
Why?
|
| Aged | 22 | 2020 | 168617 | 0.120 |
Why?
|
| Antithrombins | 1 | 2017 | 313 | 0.120 |
Why?
|
| Humans | 46 | 2023 | 759255 | 0.120 |
Why?
|
| Platelet Activation | 2 | 2015 | 661 | 0.110 |
Why?
|
| Prospective Studies | 18 | 2023 | 54204 | 0.110 |
Why?
|
| Male | 34 | 2021 | 358719 | 0.110 |
Why?
|
| Female | 34 | 2021 | 390240 | 0.110 |
Why?
|
| Hematoma | 1 | 2018 | 769 | 0.110 |
Why?
|
| Piperazines | 3 | 2015 | 2517 | 0.110 |
Why?
|
| Blood Gas Analysis | 1 | 2014 | 378 | 0.110 |
Why?
|
| Shock | 1 | 2015 | 318 | 0.110 |
Why?
|
| Catheterization | 1 | 2017 | 1433 | 0.100 |
Why?
|
| Amiodarone | 1 | 2013 | 218 | 0.100 |
Why?
|
| Troponin I | 2 | 2018 | 634 | 0.100 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2012 | 140 | 0.100 |
Why?
|
| Cardiac Output, Low | 1 | 2012 | 192 | 0.100 |
Why?
|
| Thrombocythemia, Essential | 1 | 2011 | 107 | 0.090 |
Why?
|
| Electric Countershock | 1 | 2013 | 537 | 0.090 |
Why?
|
| Epinephrine | 1 | 2013 | 791 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2018 | 1180 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 1503 | 0.080 |
Why?
|
| Random Allocation | 1 | 2013 | 2393 | 0.080 |
Why?
|
| Time Factors | 8 | 2020 | 40109 | 0.080 |
Why?
|
| Isosorbide Dinitrate | 1 | 2008 | 37 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 2852 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2020 | 2313 | 0.080 |
Why?
|
| Heart Ventricles | 2 | 2018 | 3802 | 0.080 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 1910 | 0.080 |
Why?
|
| Gastroesophageal Reflux | 1 | 2015 | 817 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 3468 | 0.070 |
Why?
|
| Cerebrovascular Disorders | 1 | 2015 | 1498 | 0.070 |
Why?
|
| Fluoroscopy | 2 | 2021 | 944 | 0.070 |
Why?
|
| Respiration, Artificial | 2 | 2020 | 2616 | 0.070 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 822 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 1999 | 0.070 |
Why?
|
| Radial Artery | 1 | 2008 | 197 | 0.070 |
Why?
|
| Myocardium | 1 | 2019 | 4680 | 0.070 |
Why?
|
| Survival Rate | 3 | 2019 | 12800 | 0.070 |
Why?
|
| Arachidonic Acid | 3 | 2012 | 434 | 0.070 |
Why?
|
| Adult | 11 | 2020 | 219390 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 1783 | 0.060 |
Why?
|
| Vasoconstriction | 1 | 2008 | 592 | 0.060 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2012 | 693 | 0.060 |
Why?
|
| Lidocaine | 1 | 2008 | 538 | 0.060 |
Why?
|
| Heart | 1 | 2018 | 4390 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2017 | 5120 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 4312 | 0.060 |
Why?
|
| Radiography, Interventional | 2 | 2021 | 1113 | 0.060 |
Why?
|
| Cerebrovascular Circulation | 1 | 2014 | 2725 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 976 | 0.060 |
Why?
|
| Risk Assessment | 5 | 2020 | 24049 | 0.060 |
Why?
|
| Radiation Dosage | 2 | 2021 | 1955 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2016 | 10185 | 0.050 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 1857 | 0.050 |
Why?
|
| Blood Flow Velocity | 2 | 2018 | 1371 | 0.050 |
Why?
|
| Cross-Over Studies | 3 | 2014 | 2058 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2008 | 1001 | 0.050 |
Why?
|
| Drug Resistance | 3 | 2012 | 1611 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 5880 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2012 | 2128 | 0.050 |
Why?
|
| Echocardiography | 1 | 2013 | 4971 | 0.050 |
Why?
|
| Bundle-Branch Block | 1 | 2002 | 281 | 0.040 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2002 | 432 | 0.040 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 15264 | 0.040 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 58867 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 4898 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 14652 | 0.040 |
Why?
|
| Hospitalization | 2 | 2020 | 10734 | 0.040 |
Why?
|
| Autopsy | 1 | 2022 | 1006 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 18110 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 429 | 0.040 |
Why?
|
| Animals | 4 | 2019 | 167838 | 0.040 |
Why?
|
| Portugal | 1 | 2017 | 90 | 0.040 |
Why?
|
| Pulsatile Flow | 1 | 2018 | 319 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2020 | 562 | 0.030 |
Why?
|
| Asthma | 1 | 2015 | 6161 | 0.030 |
Why?
|
| Polymers | 1 | 2023 | 1618 | 0.030 |
Why?
|
| Hirudins | 1 | 2017 | 194 | 0.030 |
Why?
|
| Patient Admission | 2 | 2015 | 1383 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 39216 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2018 | 691 | 0.030 |
Why?
|
| Hemodynamics | 2 | 2018 | 4164 | 0.030 |
Why?
|
| Europe | 1 | 2021 | 3429 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2018 | 638 | 0.030 |
Why?
|
| Risk Factors | 5 | 2020 | 74167 | 0.030 |
Why?
|
| Emergencies | 1 | 2020 | 1217 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1574 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2020 | 865 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2012 | 6242 | 0.030 |
Why?
|
| Jugular Veins | 1 | 2014 | 211 | 0.030 |
Why?
|
| Thrombectomy | 1 | 2018 | 708 | 0.030 |
Why?
|
| Hospital Mortality | 2 | 2020 | 5414 | 0.030 |
Why?
|
| Heart Failure | 1 | 2017 | 11833 | 0.030 |
Why?
|
| Anticoagulants | 2 | 2018 | 4897 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2018 | 1577 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2011 | 41247 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2023 | 3112 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2015 | 887 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2023 | 3606 | 0.020 |
Why?
|
| Thromboxane A2 | 1 | 2010 | 91 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 1342 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2013 | 597 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2020 | 2274 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3930 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2023 | 2873 | 0.020 |
Why?
|
| Prevalence | 2 | 2018 | 15641 | 0.020 |
Why?
|
| Heparin | 1 | 2017 | 1656 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 15815 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 2509 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 25860 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 2009 | 429 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 12268 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2015 | 1550 | 0.020 |
Why?
|
| Spasm | 1 | 2008 | 131 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2016 | 4046 | 0.020 |
Why?
|
| Skin | 1 | 2021 | 4467 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 1840 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 6542 | 0.020 |
Why?
|
| Brain | 1 | 2014 | 26863 | 0.020 |
Why?
|
| Punctures | 1 | 2008 | 368 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 679 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6532 | 0.020 |
Why?
|
| Heart-Assist Devices | 1 | 2017 | 1291 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2012 | 1108 | 0.020 |
Why?
|
| Research Design | 1 | 2021 | 6168 | 0.020 |
Why?
|
| Prognosis | 2 | 2017 | 29561 | 0.020 |
Why?
|
| Acute Disease | 1 | 2016 | 7262 | 0.020 |
Why?
|
| Incidence | 1 | 2023 | 21336 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 4269 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2009 | 12386 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 6496 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2010 | 966 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2018 | 8540 | 0.010 |
Why?
|
| Reference Values | 1 | 2011 | 4918 | 0.010 |
Why?
|
| ROC Curve | 1 | 2011 | 3570 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13479 | 0.010 |
Why?
|
| Linear Models | 1 | 2013 | 5876 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2016 | 3128 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 9269 | 0.010 |
Why?
|
| Adolescent | 3 | 2019 | 87560 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2012 | 2878 | 0.010 |
Why?
|
| Comorbidity | 1 | 2015 | 10547 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2014 | 3731 | 0.010 |
Why?
|
| Age Factors | 1 | 2017 | 18394 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2018 | 21988 | 0.010 |
Why?
|
| Decision Making | 1 | 2013 | 3920 | 0.010 |
Why?
|
| Critical Care | 1 | 2012 | 2697 | 0.010 |
Why?
|
| Contrast Media | 1 | 2012 | 5302 | 0.010 |
Why?
|
| Critical Illness | 1 | 2011 | 2707 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2010 | 9711 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2008 | 3512 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2008 | 5194 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 12964 | 0.010 |
Why?
|
| Logistic Models | 1 | 2011 | 13309 | 0.010 |
Why?
|
| Pain | 1 | 2008 | 5058 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 58483 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 15728 | 0.010 |
Why?
|
| United States | 1 | 2015 | 72237 | 0.000 |
Why?
|
| Child | 1 | 2015 | 79623 | 0.000 |
Why?
|
Concepts
(211)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(1)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_